93 related articles for article (PubMed ID: 6792664)
21. Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy.
Merito M; Giorgi Rossi P; Mantovani J; Curtale F; Borgia P; Guasticchi G
Vaccine; 2007 Jan; 25(3):458-65. PubMed ID: 17049685
[TBL] [Abstract][Full Text] [Related]
22. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of influenza and pneumococcal vaccinations among elderly people in Japan.
Cai L; Uchiyama H; Yanagisawa S; Kamae I
Kobe J Med Sci; 2006; 52(3-4):97-109. PubMed ID: 16855372
[TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects.
Claes C; Reinert RR; von der Schulenburg JM
Eur J Health Econ; 2009 Feb; 10(1):25-38. PubMed ID: 18379830
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries.
Ament A; Baltussen R; Duru G; Rigaud-Bully C; de Graeve D; Ortqvist A; Jönsson B; Verhaegen J; Gaillat J; Christie P; Cifre AS; Vivas D; Loiseau C; Fedson DS
Clin Infect Dis; 2000 Aug; 31(2):444-50. PubMed ID: 10987703
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects.
Ray GT; Whitney CG; Fireman BH; Ciuryla V; Black SB
Pediatr Infect Dis J; 2006 Jun; 25(6):494-501. PubMed ID: 16732146
[TBL] [Abstract][Full Text] [Related]
28. Streptococcus pneumoniae-related illnesses in young children: secular trends and regional variation.
Poehling KA; Szilagyi PG; Edwards K; Mitchel E; Barth R; Hughes H; Lafleur B; Schaffer SJ; Schwartz B; Griffin MR
Pediatr Infect Dis J; 2003 May; 22(5):413-8. PubMed ID: 12792380
[TBL] [Abstract][Full Text] [Related]
29. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants.
Prescrire Int; 2006 Dec; 15(86):227-33. PubMed ID: 17167934
[TBL] [Abstract][Full Text] [Related]
30. Pneumococcal vaccination.
Williams RM
Lippincotts Prim Care Pract; 1998; 2(6):625-33. PubMed ID: 9883157
[TBL] [Abstract][Full Text] [Related]
31. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.
Vila-Corcoles A; Salsench E; Rodriguez-Blanco T; Ochoa-Gondar O; de Diego C; Valdivieso A; Hospital I; Gomez-Bertomeu F; Raga X
Vaccine; 2009 Mar; 27(10):1504-10. PubMed ID: 19171174
[TBL] [Abstract][Full Text] [Related]
32. Invasive pneumococcal disease among White Mountain Apache adults, 1991-2005.
Bliss SJ; Larzalere-Hinton F; Lacapa R; Eagle KR; Frizzell F; Parkinson A; Reid R; Craig M; Santosham M; O'Brien KL
Arch Intern Med; 2008 Apr; 168(7):749-55. PubMed ID: 18413558
[TBL] [Abstract][Full Text] [Related]
33. [The elderly should be vaccinated against pneumococci].
Ortqvist A; Hedlund J; Kalin M
Lakartidningen; 1999 Mar; 96(11):1305-8. PubMed ID: 10194909
[TBL] [Abstract][Full Text] [Related]
34. Pneumococcal vaccine recommendation. American College of Physicians; Philadelphia, Pennsylvania Endorsed by the advisory committee on immunization practices, council of medical societies.
Ann Intern Med; 1982 Feb; 96(2):206-7. PubMed ID: 7059068
[TBL] [Abstract][Full Text] [Related]
35. [Pneumococcal vaccination in adults].
Jonkers RE; Boersma WG
Ned Tijdschr Geneeskd; 2003 Mar; 147(10):437-41. PubMed ID: 12666513
[TBL] [Abstract][Full Text] [Related]
36. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.
Lebel MH; Kellner JD; Ford-Jones EL; Hvidsten K; Wang EC; Ciuryla V; Arikian S; Casciano R
Clin Infect Dis; 2003 Feb; 36(3):259-68. PubMed ID: 12539065
[TBL] [Abstract][Full Text] [Related]
37. New vaccines against otitis media: projected benefits and cost-effectiveness.
O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
[TBL] [Abstract][Full Text] [Related]
38. A cost-benefit analysis of immunization for pneumococcal pneumonia.
Patrick KM; Woolley FR
JAMA; 1981 Feb; 245(5):473-7. PubMed ID: 6779017
[TBL] [Abstract][Full Text] [Related]
39. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
Hubben GA; Bos JM; Glynn DM; van der Ende A; van Alphen L; Postma MJ
Vaccine; 2007 May; 25(18):3669-78. PubMed ID: 17360082
[TBL] [Abstract][Full Text] [Related]
40. [Antipneumococcal vaccine: up date and prospective].
Caramia G; Pastorelli G
Minerva Pediatr; 2005 Oct; 57(5):229-41. PubMed ID: 16205607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
